Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity

Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity

Publication date: Dec 04, 2019

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has entered into a partnership with Ethicann Pharmaceuticals Inc. (“Ethicann”), a Calgary-based pharmaceutical company using botanically sourced cannabinoid oils to formulate prescription drugs.

The program will initially focus on using Catalent’s proven Zydis(R) orally disintegrating tablet technology to develop a new combination pharmaceutical-grade cannabidiol (CBD) and tetrahydrocannabinol (THC) product that, if approved, would treat patients suffering from multiple sclerosis (MS) spasticity.

SOMERSET, N. J., Dec. 3, 2019 /PRNewswire-PRWeb/ — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has entered into a partnership with Ethicann Pharmaceuticals Inc. (“Ethicann”), a Calgary-based pharmaceutical company using botanically sourced cannabinoid oils to formulate prescription drugs.

The program will initially focus on using Catalent’s proven Zydis(R) orally disintegrating tablet technology to develop a new combination pharmaceutical-grade cannabidiol (CBD) and tetrahydrocannabinol (THC) product that, if approved, would treat patients suffering from multiple sclerosis (MS) spasticity.

Concepts Keywords
Bioavailable Cannabinoids
Biologics Appetite stimulants
Calgary Entheogens
Canada Euphoriants
Cannabidiol Catalent
Cannabinoid Zydis
Cannabinoids Orally disintegrating tablet
CBD Tetrahydrocannabinol
CBDs Http
Chemotherapy Drug delivery
Chronic Pain Zydis Ultra technology
Dosage Form Chemotherapy
Drug Delivery Dosage forms
FDA Pharmacology
Fiscal Year Health
Inadequate Drugs
Metabolism Chemotherapy
Multiple Sclerosis Nausea
Muscle Spasms Stress disorder PTSD
Nausea Developmental therapeutic product
Opioid
Pharmaceutical
Pharmaceutical Company
President
PRWeb
PTSD
Somerset
SOMERSET
Spasticity
Stiffness
Sublingual
Swindon
Tablets
Tetrahydrocannabinol
THC
Vomiting

Semantics

Type Source Name
drug DRUGBANK Coenzyme M
disease MESH Multiple Sclerosis
disease MESH development
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Cannabidiol
drug DRUGBANK Dronabinol
disease MESH suffering
disease MESH chronic pain
disease MESH post-traumatic stress disorder

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *